Ryu Watanabe

4.2k total citations · 1 hit paper
125 papers, 2.7k citations indexed

About

Ryu Watanabe is a scholar working on Rheumatology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Ryu Watanabe has authored 125 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Rheumatology, 40 papers in Pulmonary and Respiratory Medicine and 34 papers in Immunology. Recurrent topics in Ryu Watanabe's work include Vasculitis and related conditions (36 papers), Systemic Lupus Erythematosus Research (30 papers) and Atherosclerosis and Cardiovascular Diseases (25 papers). Ryu Watanabe is often cited by papers focused on Vasculitis and related conditions (36 papers), Systemic Lupus Erythematosus Research (30 papers) and Atherosclerosis and Cardiovascular Diseases (25 papers). Ryu Watanabe collaborates with scholars based in Japan, United States and China. Ryu Watanabe's co-authors include Jörg J. Goronzy, Cornelia M. Weyand, Gerald J. Berry, Hui Zhang, Motomu Hashimoto, Lü Tian, Tsuyoshi Shirai, Barbara B. Wallis, John C. Giacomini and David G. Harrison and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Journal of Clinical Investigation.

In The Last Decade

Ryu Watanabe

116 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease

2016 428 citations Ryu Watanabe, Jörg J. Goronzy et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ryu Watanabe Japan	28	1.1k	987	967	522	316	125	2.7k
Joshua D. Ooi Australia	31	1.5k 1.4×	1.0k 1.1×	420 0.4×	698 1.3×	123 0.4×	85	2.7k
H. Terence Cook United Kingdom	22	824 0.8×	430 0.4×	704 0.7×	370 0.7×	139 0.4×	45	2.3k
Wayel H. Abdulahad Netherlands	39	1.9k 1.8×	1.7k 1.7×	1.3k 1.4×	667 1.3×	279 0.9×	128	4.3k
Yoshitaka Morita Japan	26	1.0k 0.9×	264 0.3×	775 0.8×	659 1.3×	251 0.8×	105	2.7k
Ping Zhu China	34	1.8k 1.6×	359 0.4×	1.2k 1.2×	1.4k 2.7×	205 0.6×	142	3.7k
Satoshi Kubo Japan	32	1.2k 1.1×	245 0.2×	1.6k 1.6×	328 0.6×	363 1.1×	157	3.0k
Barbara Tolusso Italy	30	961 0.9×	214 0.2×	1.3k 1.3×	584 1.1×	311 1.0×	129	2.9k
Kenichi Ohashi Japan	29	374 0.3×	939 1.0×	368 0.4×	1.3k 2.5×	399 1.3×	300	4.1k
Kyung Chul Moon South Korea	32	375 0.3×	1.5k 1.5×	371 0.4×	1.2k 2.4×	421 1.3×	228	3.9k
Karl Egerer Germany	26	650 0.6×	202 0.2×	900 0.9×	703 1.3×	440 1.4×	52	2.5k

Countries citing papers authored by Ryu Watanabe

Since Specialization

Citations

This map shows the geographic impact of Ryu Watanabe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryu Watanabe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryu Watanabe more than expected).

Fields of papers citing papers by Ryu Watanabe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryu Watanabe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryu Watanabe. The network helps show where Ryu Watanabe may publish in the future.

Co-authorship network of co-authors of Ryu Watanabe

This figure shows the co-authorship network connecting the top 25 collaborators of Ryu Watanabe. A scholar is included among the top collaborators of Ryu Watanabe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryu Watanabe. Ryu Watanabe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kotani, Takuya, Keisuke Fukui, Ryu Watanabe, et al.. (2025). Identification of novel clinical subtypes in patients with microscopic polyangiitis using cluster analysis: multicenter REVEAL cohort study. Frontiers in Immunology. 15. 1450153–1450153. 1 indexed citations

Watanabe, Ryu, Yoshiya Tanaka, Tsutomu Takeuchi, et al.. (2025). Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial. Lara D. Veeken. 64(7). 4190–4199. 1 indexed citations

Watanabe, Ryu, Takuya Kotani, Yuichi Masuda, et al.. (2024). Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study. Frontiers in Immunology. 15. 1457202–1457202. 5 indexed citations

Kotani, Takuya, Daisuke Nishioka, Yuichi Masuda, et al.. (2024). Poor prognostic factors for relapse of interstitial lung disease in microscopic polyangiitis: the Japanese multicentre REVEAL cohort study. Arthritis Research & Therapy. 26(1). 221–221. 1 indexed citations

Ohtsuki, Shozo, Chenyao Wang, Ryu Watanabe, et al.. (2023). Deficiency of the CD155-CD96 immune checkpoint controls IL-9 production in giant cell arteritis. Cell Reports Medicine. 4(4). 101012–101012. 17 indexed citations

Iwasaki, Takashi, Ryu Watanabe, Hiromu Ito, et al.. (2023). POS0241 MONOCYTE-DERIVED TRANSCRIPTOMES EXPLAIN THE INEFFECTIVENESS OF ABATACEPT IN RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. 82. 353–354. 1 indexed citations

Doi, Hiroshi, Ryu Watanabe, Koichi Murata, et al.. (2023). Factors associated with osteoporosis and fractures in patients with systemic lupus erythematosus: Kyoto Lupus Cohort. Modern Rheumatology. 34(1). 113–121. 4 indexed citations

Watanabe, Ryu, et al.. (2023). Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update. International Journal of Molecular Sciences. 24(6). 5643–5643. 15 indexed citations

Watanabe, Ryu, Kosaku Murakami, Hiromu Ito, et al.. (2023). Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort. Immunological Medicine. 46(2). 84–92. 1 indexed citations

10.

Kotani, Takuya, Daisuke Nishioka, Ryu Watanabe, et al.. (2023). Prediction model for respiratory-related mortality in microscopic polyangiitis with interstitial lung disease: multicentre REVEAL cohort study. Lara D. Veeken. 63(6). 1607–1615. 8 indexed citations

11.

Tsuji, Hideaki, Nobuo Kuramoto, Mirei Shirakashi, et al.. (2022). Autoantibody profiles associated with morbidity and mortality in scleroderma renal crisis. Lara D. Veeken. 61(10). 4130–4135. 9 indexed citations

12.

Murata, Koichi, Shuji Ito, Akari Suzuki, et al.. (2022). Role of Lysine‐Specific Demethylase 1 in Metabolically Integrating Osteoclast Differentiation and Inflammatory Bone Resorption Through Hypoxia‐Inducible Factor 1α and E2F1. Arthritis & Rheumatology. 74(6). 948–960. 44 indexed citations

13.

Shirakashi, Mirei, Mikako Maruya, Keiji Hirota, et al.. (2021). Effect of Impaired T Cell Receptor Signaling on the Gut Microbiota in a Mouse Model of Systemic Autoimmunity. Arthritis & Rheumatology. 74(4). 641–653. 30 indexed citations

14.

Watanabe, Ryu, Motomu Hashimoto, Koichi Murata, et al.. (2021). Neutrophil count reduction 1 month after initiating tocilizumab can predict clinical remission within 1 year in rheumatoid arthritis patients. Rheumatology International. 42(11). 1983–1991. 5 indexed citations

15.

Hashimoto, Motomu, Yoshihito Fujita, Kaori Ikeda, et al.. (2021). Urinary sodium-to-potassium ratio associates with hypertension and current disease activity in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Research & Therapy. 23(1). 96–96. 10 indexed citations

16.

Itaya, Takahiro, Mie Torii, Motomu Hashimoto, et al.. (2021). Perceptions and behaviours related to COVID-19 in patients with rheumatoid arthritis: a cross-sectional study. Clinical Rheumatology. 41(1). 45–51. 2 indexed citations

17.

Watanabe, Ryu, Motomu Hashimoto, Koichi Murata, et al.. (2021). Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunological Medicine. 45(1). 35–44. 43 indexed citations

18.

Watanabe, Ryu, T Iwasaki, Koji Kitagori, et al.. (2021). POS0345 CLINICOGENETIC STUDY OF FIVE NOVEL SUSCEPTIBILITY LOCI FOR TAKAYASU ARTERITIS: SUSCEPTIBILITY LOCI IN THE IL12B AND PTK2B REGION, BUT NOT THE LILRA3, DUSP22, KLHL33 REGIONS, ARE ASSOCIATED WITH VASCULAR DAMAGE IN TAKAYASU ARTERITIS. Annals of the Rheumatic Diseases. 80. 401–402. 1 indexed citations

19.

Watanabe, Ryu, Hui Zhang, Gerald J. Berry, et al.. (2019). OP0141 #X00A0; CD28 AS A POTENTIAL THERAPEUTIC TARGET FOR GIANT CELL ARTERITIS. Annals of the Rheumatic Diseases. 78. 146–146. 2 indexed citations

20.

Wen, Zhenke, Yi Shen, Gerald J. Berry, et al.. (2017). The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway. Science Translational Medicine. 9(399). 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact